---
schema_version: "secwatch.filing_event.v1"
accession: "0000920148-26-000098"
form_type: "8-K"
ticker: "LH"
cik: "0000920148"
company_name: "LABCORP HOLDINGS INC."
filed_at: "2026-02-17T23:59:59+00:00"
generated_at: "2026-05-16T02:40:31.564836+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Labcorp Q4 revenue $3.52B (+5.6% YoY), adj EPS $4.07 beat; guides FY26 adj EPS $17.55-18.25

## Summary
- Q4 revenue $3.52B (up 5.6% YoY, organic 3.8%); diluted EPS $1.98; adjusted EPS $4.07 vs $3.45.
- Full-year 2025 revenue $13.95B (+7.2% YoY); adj EPS $16.44 (+12.8% YoY); free cash flow $1.21B.
- 2026 guidance: revenue $14.61-14.79B (midpoint +5.4%), adj EPS $17.55-18.25 (midpoint +8.9%), FCF $1.24-1.36B.
- Diagnostics revenue $2.73B (+5.5%); adj op margin 15.4% (up 150 bps). Biopharma Central Labs grew 11.1%.
- Repurchased $450M stock in 2025; declared $0.72/share dividend payable Mar 12, 2026; signed 13 lab partnership deals.

## SEC filing metadata
- accession: 0000920148-26-000098
- form_type: 8-K
- ticker: LH
- cik: 0000920148
- company_name: LABCORP HOLDINGS INC.
- filed_at: 2026-02-17T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/920148/000092014826000098/0000920148-26-000098-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/920148/000092014826000098/lh-20260217.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000920148-26-000098
- JSON: https://secwatch.observer/filing/0000920148-26-000098.json
- Plain text: https://secwatch.observer/filing/0000920148-26-000098.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.